Beta Bionics CFO granted 110,342 stock options

Beta Bionics, Inc. reported that Chief Financial Officer Stephen Feider received a grant of employee stock options covering 110,342 shares of common stock.

Rhea-AI Filing Summary

Beta Bionics, Inc. reported that Chief Financial Officer Stephen Feider received a grant of employee stock options covering 110,342 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036.

The grant was awarded as compensation and did not involve any open-market buying or selling. According to the terms, the options vest in 36 equal monthly installments starting on March 1, 2026, meaning the CFO earns the right to exercise them gradually over three years.

Insider Trade Summary

Grant/Award: 110,342 shares

Grant/Award 1 txn

Insider Feider Stephen

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	110,342	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 110,342 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) report for its CFO?

Beta Bionics reported that CFO Stephen Feider received a grant of 110,342 employee stock options. These options relate to the company’s common stock and represent a compensation award, not an open-market purchase or sale of existing shares by the executive.

What is the exercise price of the new Beta Bionics (BBNX) CFO stock options?

The newly granted stock options to the Beta Bionics CFO have an exercise price of $12.63 per share. This means he can later buy common shares at $12.63, regardless of the market price, once the options are vested and exercisable.

How many Beta Bionics (BBNX) shares are covered by the CFO’s option grant?

The CFO’s option grant covers 110,342 shares of Beta Bionics common stock. These are derivative securities, giving the right to purchase that number of shares at the fixed exercise price once vesting and other conditions are satisfied over time.

When do the Beta Bionics (BBNX) CFO stock options vest?

The stock options granted to the Beta Bionics CFO vest in 36 equal monthly installments beginning March 1, 2026. This creates a three-year vesting schedule, so he gains the right to exercise an additional portion of the options each month during that period.

When do the newly granted Beta Bionics (BBNX) CFO options expire?

The newly granted stock options to the Beta Bionics CFO expire on February 26, 2036. If they are not exercised by that expiration date, any unexercised options will lapse and no longer provide the right to purchase Beta Bionics common stock.

Did the Beta Bionics (BBNX) CFO buy or sell shares in the market in this filing?

No market buy or sell occurred. The Form 4/A shows a compensation-related grant of employee stock options to the CFO, coded as an acquisition (A). It reflects an award of derivative securities, not an open-market transaction in existing Beta Bionics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		110,342		(1)	02/26/2036	Common Stock	110,342	$0	110,342	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

	/s/ Stephen Feider	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.